Jump to content

Martin Shkreli

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by E. Fokker (talk | contribs) at 00:31, 27 October 2015 (Reverted 1 edit by 113.59.194.79 (talk) to last revision by 2601:644:401:6EA7:8C95:D064:B35F:CE96. (TW)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Martin Shkreli
Born (1983-04-01) April 1, 1983 (age 41)
Brooklyn, New York, United States
NationalityAmerican
Alma materBaruch College
Occupation(s)corporate executive, hedge fund manager, entrepreneur
OrganizationTuring Pharmaceuticals

Martin Shkreli (born April 1, 1983) is an American hedge fund manager and entrepreneur, specializing in healthcare businesses, and is a co-founder of MSMB Capital Management and the founder of Turing Pharmaceuticals AG. He is a co-founder and was the chief executive officer of Retrophin LLC, a biotechnology firm founded in 2011.[1][2] In September 2015, Shkreli was criticized when Turing Pharmaceuticals obtained the manufacturing license for Daraprim, and raised its price by 5,455 percent (from $13.50 to $750 per tablet). After initially defending the price increase, Shkreli said an unspecified lower price would be established.

Early life

Martin Shkreli, the son of Albanian and Croatian immigrants, was born in Brooklyn, New York on April 1, 1983.[3] He grew up in a working-class community in Brooklyn. Shkreli skipped several grades in school and received a degree in business from New York's Baruch College in 2004.[3]

Career

In 2000, Shkreli was a college intern and then clerk at Jim Cramer's Cramer, Berkowitz, & Co. After four years at Cramer Berkowitz, he held jobs at UBS and Intrepid Capital Management before starting his first hedge fund, Elea Capital Management, in 2006. Shkreli launched MSMB Capital Management (named after the two founding Portfolio Managers, Martin Shkreli and Marek Biestek) in 2009.[4][5] In 2011, Shkreli filed requests with the U.S. Food and Drug Administration (FDA) to reject a new type of cancer diagnostic from the manufacturers Navidea Biopharmaceuticals and an inhalable insulin therapy for diabetes from MannKind Corporation, while publicly short-selling the companies' stocks. Both companies' stock values immediately dropped following Shkreli's interventions, and the companies had difficulty launching the products as a result. The FDA subsequently approved both therapies.[6][5]

Retrophin

Retrophin Inc. was created in 2011[5] and run from the offices of MSMB Capital as a portfolio company with an emphasis on biotechnology, to create treatments for orphan diseases.[2] In September 2014 Retrophin acquired the rights to Thiola, a drug used to treat the rare disease cystinuria. Shkreli resigned from the company in October 2014 after Retrophin's Board decided to replace him that September[7] with Stephen Aselage.[8] Shkreli then left Retrophin and started Turing Pharmaceuticals. Retrophin filed a $65 million lawsuit against Shkreli in August 2015,[7] claiming he breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds,[9][10] and alleging that he "committed stock-trading irregularities and other violations of securities rules".[11] The lawsuit includes the claim that Shkreli threatened and harassed a former MSMB employee and his family.[11] Shkreli and some of his business associates have been under criminal investigation by the U.S. Attorney for the Eastern District of New York since January 2015 with respect to their Retrophin activities, and Shkreli has invoked his Fifth Amendment right against self-incrimination in order to avoid testifying during civil depositions.[12][13]

Turing Pharmaceuticals

In February 2015, Shkreli launched Turing Pharmaceuticals with three drugs in development, acquired from Retrophin: an intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension.[14]

As executive chairman of Turing Pharmaceuticals, in August 2015 Shkreli raised the price of Daraprim from $13.50 per pill to $750 per pill—a 5,455% increase[15]—shortly after purchasing the marketing rights to the drug for $55 million from Impax Laboratories.[16] While the pharmaceutical patent for the 1953 drug has long expired, no company in the US is currently manufacturing generic pyrimethamine.[17] The deal between Turing and Impax was made on the condition that Impax first remove the drug from regular wholesalers and pharmacies, making it more difficult for generic drug manufacturers to develop generic copies.[15] In June, two months before the sale to Turing was announced, Impax switched to tightly controlled distribution.[18](subscription required) Since the market for Daraprim is small, most manufacturers won't go through the expensive and time-consuming process of obtaining regulatory approval for manufacture. Turing therefore maintains a closed distribution model for Daraprim, and can set the price extremely high without fear of price competition.[19]

Price hike controversy

In September 2015, Shkreli was criticized by several health organizations[20] for obtaining manufacturing licenses on old, out-of-patent[21] life-saving medicines including pyrimethamine (brand name Daraprim), which is used to treat patients with toxoplasmosis, malaria, some cancers, and AIDS,[22] and then increasing the price of the drug in the US from $13.50 to $750 per pill, a 5,455% increase.[15][23][12] In an interview with Bloomberg News, Shkreli claimed that despite the price increase patient co-pays would actually be lower, that many patients would get the drug at no cost, that the company has expanded its free drug program, and that it sells half of the drugs for one dollar.[24] Shkreli defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime."[25][26]

The price increase[27] has been criticized by Hillary Clinton,[22] the HIV[28] Medicine Association,[29] the Infectious Diseases Society of America,[15] the lobbying group Pharmaceutical Research and Manufacturers of America,[30] Donald Trump,[31] and Bernie Sanders.[32] The record label Collect Records publicly ended its business relationship with Shkreli, who had invested in the company.[33]

A few days later, Shkreli[34][35] announced that he plans to lower the price by an unspecified amount, "in response to the anger that was felt by people".[36][35][12] As of October 8th, the price has not been reduced. [37] Following a request by U.S. Senators Bernie Sanders and Elijah Cummings for details of Turing Pharmaceuticals' finances and price-setting practices in September 2015,[38] the company hired four lobbyists from Buchanan, Ingersoll & Rooney with backgrounds in health care legislation and pharmaceutical pricing.[39][40] In addition to the lobbyists, Shkreli hired a crisis public relations firm to help explain the pricing decision.[41]

On October 22, 2015, Imprimis Pharmaceuticals said it would begin selling a very similar, but not identical drug, for $1 per pill.[42]

eSports involvement

Shkreli is a League of Legends player who goes by the name "Cerebral" and began expressing interest in purchasing an eSports team in 2014.[43] In May, Enemy eSports announced that they had rejected a $1.2 million offer from Shkreli.[44] Eventually he founded his own team, Odyssey eSports, and aimed to qualify for the 2015 North American League of Legends Challenger Series. The team lost to Cloud9 Tempest in the qualifying tournament and failed to qualify. In August, Odyssey merged with Imagine, with Shkreli becoming Chairman of the team. During the merger the team also acquired the Dota 2 team Leviathan.[45][46]

References

  1. ^ Nussbaum, Alex (Aug 3, 2011). "MSMB Capital Makes Unsolicited $378M Bid For AMAG Pharmaceuticals". Bloomberg.
  2. ^ a b "Retrophin: About Us". Archived from the original on 2011-12-30.
  3. ^ a b "Who is Martin Shkreli - 'the most hated man in America'?". BBC. September 23, 2015.
  4. ^ "Pfizer Board comes under fire". Financial Times. Dec 8, 2010.
  5. ^ a b c Barrett, Paul (April 17, 2014). "Retrophin's Martin Shkreli, the Biotech Short Seller Who Went Long ("Once a Notorious Short Seller, Martin Shkreli Now Sees a Future in Biotech")". Bloomberg Business. Bloomberg.Com. Retrieved September 22, 2015.
  6. ^ "Biotech exec Martin Shkreli has history of tough tactics". Stat. Boston Globe. September 26, 2015. Retrieved September 28, 2015. {{cite news}}: Unknown parameter |registration= ignored (|url-access= suggested) (help)
  7. ^ a b United States District Court for the Southern District of New York (August 17, 2015). "EX-99.1, Retrophin, Inc. v. Martin Shkreli". SEC.gov (EDGAR). United States Securities and Exchange Commission. Retrieved September 22, 2015.
  8. ^ "Stephen J. Aselage bio". Bloomberg.Com. Bloomberg News. Retrieved September 22, 2015.
  9. ^ "Retrophin Sues Founder in Latest Fight Over Use of Funds". Bloomberg Business News. 2015-08-17. Retrieved 2015-09-22.
  10. ^ "Retrophin Sues Founder Martin Shkreli For $65M. His Reply: 'Preposterous'". Forbes.com. August 15, 2015. Retrieved September 22, 2015.
  11. ^ a b "Price-Gouging Pharma CEO Under Investigation for Insider Trading and Fraud". US Uncut. September 22, 2015. Retrieved September 28, 2015.
  12. ^ a b c "Federal Prosecutors Target Martin Shkreli in a Criminal Investigation". Newsweek. September 23, 2015. Retrieved September 27, 2015. {{cite news}}: Unknown parameter |subscription= ignored (|url-access= suggested) (help)
  13. ^ "Biotech's 'Boy Genius' Faces New Allegations of Wrongdoing". Bloomberg News. February 23, 2015. Retrieved September 28, 2015.
  14. ^ Weintraub, Arlene (February 27, 2015). "Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin". Forbes. Retrieved September 24, 2015.
  15. ^ a b c d "Drug Goes From $13.50 a Tablet to $750, Overnight". The New York Times. Sep 20, 2015.
  16. ^ James Woods. "Company Hikes Price 5,000% For Life-Saving Cancer and AIDS Drug". U.S. Uncut.
  17. ^ "Company Acquires Rights To Drug Used By AIDS/Cancer Patients; Immediately Raises Per Pill Price From Under $14 To $750". Techdirt. 2015-09-19.
  18. ^ "Martin Shkreli, the Mercurial Man Behind the Drug Price Increase That Went Viral". New York Times. September 22, 2015. Retrieved October 10, 2015.
  19. ^ James Surowiecki (12 October 2015). "Martin Shkreli Is Not the Problem". The New Yorker.
  20. ^ "Daraprim Price Hike Controversy". snopes.com.
  21. ^ "Martin Shkreli Has One Idea, And It's a Bad One". sciencemag.org.
  22. ^ a b Long, Heather; Egan, Matt; Dodley, Dominique (September 22, 2015). "Meet the guy behind the $750 AIDS drug". Money.CNN.com. Retrieved September 23, 2015.
  23. ^ "Martin Shkreli Will No Longer Price-Gouge AIDS Patients — What To Read". digg.com.
  24. ^ "Drug Goes From $13.50 to $750 Overnight" Bloomberg News, 2:30, retrieved September 23, 2015]
  25. ^ Ramsey, Lydia (22 Sep 2015). "A pharma CEO tried to defend his decision to jack up the price of a critical drug by 5,000% — and it backfired". Business Insider.
  26. ^ Reuters (22 Sep 2015). "Company hikes price of popular drug". Reuters. {{cite news}}: |last1= has generic name (help)
  27. ^ Carolyn Johnson (21 September 2015). "How an obscure drug's 4,000% price increase might finally spur action on soaring health-care costs". Washington Post.
  28. ^ "Mad Men Actor Talks to Expert About Meds Whose Price Was Raised Nearly 5000 Percent Overnight". HIVPlusMag.com.
  29. ^ "Letter from the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA)" (PDF). hivma. Infectious Diseases Society of America. Retrieved September 23, 2015.
  30. ^ Bloomfield, Doni (September 22, 2015). "Drug CEO Targeted by Clinton Is Criticized by Drug Lobby". Bloomberg.com. Retrieved September 23, 2015.
  31. ^ LoGiurato, Brett. "Donald Trump trashes former hedge-fund guy who jacked up drug price: 'He looks like a spoiled brat'". Business Insider. Retrieved September 23, 2015.
  32. ^ Eunjung Cha, Ariana (September 22, 2015). "CEO who raised price of old pill more than $700 calls journalist a 'moron' for asking why". The Washington Post. Retrieved September 23, 2015.
  33. ^ "Label cuts ties with hedge fund man who boosted Aids drug price 5,000%". The Guardian. September 25, 2015. Retrieved September 28, 2015.
  34. ^ "Tweets with replies by Martin Shkreli (@MartinShkreli) - Twitter". twitter.com.
  35. ^ a b Let's Get in the Middle Of It: "Martin Shkreli". YouTube. 21 September 2015.
  36. ^ Mitchell, Andrea; Helsel, Phil (September 23, 2015). "Drug CEO Will Lower Price of Daraprim After Hike Sparked Outrage". NBC News. Retrieved September 23, 2015.
  37. ^ "Martin Shkreli update on Daraprim price". Tech Insider. 8 October 2015.
  38. ^ Bernie Sanders (September 21, 2015). "2015-09-01 EEC Sanders to Turing Pharmaceuticals" (PDF). United States House Committee on Oversight and Government Reform (Democratic Party). Retrieved October 9, 2015.
  39. ^ "Drug firm maligned for 5,000 percent price hike turns to K Street for help". The Hill.
  40. ^ Catherine Ho (7 October 2015). "Working for 'the most hated man in America'". Washington Post.
  41. ^ Tannahill, Jason (9 Oct 2015). "PR Man Allan Ripp Representing The "Most Hated Man in America"". EverythingPR.
  42. ^ Competitor to Offer $1 Pill After Turing Price Hike Outrage, NBC News, October 22, 2015
  43. ^ Wolf, Jacob (May 6, 2015). "Millionaire pharmaceutical CEO set to shake up Challenger scene with new team". The Daily Dot. Retrieved August 27, 2015.
  44. ^ WEBER, ALEXANDRE "DRPUPPET" (May 4, 2015). "Enemy Esports Turned Down $1.2 Million For Their League of Legends Team". eSports Go. Retrieved September 24, 2015.
  45. ^ Wolf, Jacob (August 7, 2015). "Imagine and Odyssey merge, add Leviathan Dota 2 squad". The Daily Dot. Retrieved August 27, 2015.
  46. ^ Ciubotaru, Andra (August 18, 2015). "Recently merged League of Legends organization adds Team Leviathan Dota 2 squad". DotaBlast. Retrieved August 27, 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Martin_Shkreli&oldid=687667047"